Baricitinib Phase 1b/2 Trial for Post-HSCT Persistent Thrombocytopenia

ClinicalTrials.gov registered a new prospective, open-label Phase 1b/2 clinical trial (NCT07535645) investigating baricitinib for treatment of persistent thrombocytopenia in patients who have undergone allogeneic hematopoietic stem cell transplantation and are refractory to thrombopoietin receptor agonists. The trial is registered as Phase 1 with an anticipated start date of April 17, 2026.

Affected parties including pharmaceutical companies manufacturing baricitinib, clinical investigators, and healthcare providers conducting stem cell transplantation procedures should monitor this trial for emerging safety and efficacy data. Trial results may inform future label expansions or clinical practice guidelines for managing post-transplant hematologic complications.